Rallybio Corporation (RLYB)
NASDAQ: RLYB · Real-Time Price · USD
0.5350
+0.0700 (15.05%)
Aug 1, 2025, 4:00 PM - Market closed

Company Description

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases.

Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.

The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.

It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases.

Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia.

The company was founded in 2018 and is headquartered in New Haven, Connecticut.

Rallybio Corporation
Rallybio logo
CountryUnited States
Founded2018
IPO DateJul 29, 2021
IndustryBiotechnology
SectorHealthcare
Employees25
CEOStephen Uden

Contact Details

Address:
234 Church Street, Suite 1020
New Haven, Connecticut 06510
United States
Phone203 859 3820
Websiterallybio.com

Stock Details

Ticker SymbolRLYB
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$13.00
CIK Code0001739410
CUSIP Number75120L100
ISIN NumberUS75120L1008
Employer ID85-1083789
SIC Code2834

Key Executives

NamePosition
Dr. Stephen Uden M.B, M.D.Co-Founder, President, Chief Executive Officer and Director
Dr. Martin W. MacKay Ph.D.Co-Founder and Chairman
Jonathan I. Lieber M.B.A.Chief Financial Officer and Treasurer
Dr. Steven W. Ryder F.A.C.P, M.D.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Jul 8, 20258-KCurrent Report
Jun 27, 20258-KCurrent Report
May 16, 20258-KCurrent Report
May 9, 2025S-8Securities to be offered to employees in employee benefit plans
May 8, 202510-QQuarterly Report
May 8, 20258-KCurrent Report
Apr 8, 20258-KCurrent Report
Apr 7, 2025DEF 14AOther definitive proxy statements
Mar 13, 20258-KCurrent Report
Mar 13, 2025424B5Filing